423 Hindry Avenue
65 articles with ImaginAb, Inc.
BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer
BriaCell Therapeutics Corp. jointly announces a multi-year, non-exclusive license agreement with ImaginAb Inc
ImaginAb Inc, a market leading global biotechnology company, focused on developing next generation immuno oncology imaging agents and therapeutic radiopharmaceuticals, announced the signing of a new significant multi-year, non-exclusive license agreement with Boehringer Ingelheim.
Latest financing will advance the clinical development of its CD8 ImmunoPET agent and build on its market leading position.
ImaginAb Inc, a leading global provider of immuno-oncology imaging agents and NEUVOGEN, an immuno-oncology company developing next generation therapeutic whole cell cancer vaccines, announced they have signed a multi-year non-exclusive licensing agreement.
ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. to supply 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.
ARTMS Announces New Appointments to Executive Leadership TeamCompany adds experienced executives to support the continued expansion of commercial activities and focus on radiopharmaceutical innovator and manufacturer relationships
ARTMS Inc., the global leader in the development and commercialization of technologies that are transforming the production of the world’s most-used diagnostic imaging isotopes, announced that it has expanded its senior management team with the addition of two industry veterans, Doug Gentilcore as Chief Commercial Officer and Mark Przekop as Vice President of Marketing and Business Development.
ImaginAb Inc. announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Penn Medicine in Philadelphia, PA. Penn Medicine is one of the world's leading academic medical centers.
ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology
ImaginAb, Inc. announced the signing of a multi-party collaboration agreement with AstraZeneca, Pfizer Inc. and Takeda Pharmaceutical Company Limited focused on furthering the clinical development of ImaginAb's CD8 ImmunoPET technology.
10/14/2019It was a busy week for clinical trial announcements. Here’s a look.
Innovation Showcase 2019 on Monday, October 14, 2019, at The Lundquist Institute (formerly LA BioMed), 1124 West Carson Street, Torrance, CA.
ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine
The data from the Phase I trial reported in the paper demonstrated 89Zr-Df-IAB22M2C was well tolerated with no immediate or delayed side effects observed.
ImaginAb Enrolls First Patient at the University of Alabama at Birmingham in On-going "Base Line/On Therapy" (BOT) Phase II Clinical Trial
ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces it has enrolled its first patient for the Phase II clinical trial of its lead product CD8 tracer, 89Zr-Df-IAB22M2C, at the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB).
ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces that it is scheduled to attend and / or present at the following investor and scientific conferences in September and October 2019.
ImaginAb Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Dana-Farber Cancer Institute in Boston, MA.
ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced that it has entered into a non-exclusive license and collaboration agreement with Roche.
ImaginAb, Inc. announces that it will attend and present at the upcoming Society of Nuclear Medicine and Molecular Imaging Annual Meeting being held June 22-25, 2019, at the Anaheim Convention Center in Anaheim, California.
ImaginAb, Inc. announces that it is scheduled to present at the following investor and scientific conferences in May and June 2019.
ImaginAb Enrolls First Patient in Phase II Clinical Trial at a World-Leading Cancer Center in Los Angeles County
ImaginAb Inc., a clinical stage immuno-oncology imaging company, announces it has enrolled its first patient for the Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at City of Hope in Los Angeles County.
ImaginAb Announces change in management and strengthening of the Board of Directors and the Scientific Advisory Board
ImaginAb, Inc., a clinical stage immuno-oncology imaging company, announced the appointment of Ian Wilson as Chief Executive Officer while Martyn Coombs steps down for family reasons, effective immediately.
ImaginAb, Inc., an emerging immuno-oncology imaging company, announced the enrollment of the first patient in the Phase II clinical trial of ImaginAb's CD8+ T Cell imaging agent.